Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Net Income (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Net Income for 2 consecutive years, with -$23.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income fell 22.31% to -$23.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$100.7 million, a N/A change, with the full-year FY2024 number at -$77.3 million, down 4.66% from a year prior.
  • Net Income was -$23.2 million for Q3 2025 at Pyxis Oncology, down from -$18.1 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$5.3 million in Q1 2024 to a low of -$37.7 million in Q4 2024.